Novartis AG (NOVN.VX)
66.60CHF
31 Jul 2013
CHF0.35 (+0.53%)
CHF66.25
CHF66.00
CHF66.95
CHF65.70
3,633,507
4,192,321
CHF73.75
CHF55.20
About
Overall
| Beta: | 0.79 |
| Market Cap (Mil.): | CHF179,553.91 |
| Shares Outstanding (Mil.): | 2,706.19 |
| Dividend: | 2.30 |
| Yield (%): | 3.45 |
Financials
| NOVN.VX | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 18.91 | 37.93 | 37.76 |
| EPS (TTM): | 3.51 | -- | -- |
| ROI: | 10.03 | 19.48 | 18.76 |
| ROE: | 14.08 | 20.17 | 19.59 |
Patient taking Novartis MS pill developed rare disease
ZURICH - A patient taking Novartis' multiple sclerosis pill Gilenya developed a rare and potentially fatal viral disease, the Swiss drugmaker said on Tuesday, an unexpected setback as it faces growing competition from new oral treatments.
U.S. court permits generic version of Teva MS drug a year sooner
WASHINGTON/NEW YORK - Teva Pharmaceutical Industries' $4 billion-a-year multiple sclerosis drug Copaxone will lose its patent protection in 2014 rather than 2015 because of a ruling from a U.S. appeals court on Friday, making it potentially prey to cheaper generics next May.
UPDATE 1-US court permits generic version of Teva MS drug a year sooner
WASHINGTON/NEW YORK, July 26 - Teva Pharmaceutical Industries' $4 billion-a-year multiple sclerosis drug Copaxone will lose its patent protection in 2014 rather than 2015 because of a ruling from a U.S. appeals court on Friday, making it potentially prey to cheaper generics next May.
Europe backs new dual-action Novartis lung drug
LONDON - Swiss drugmaker Novartis won an important endorsement of its new inhaled medicine for chronic lung disease on Friday when European regulators recommended approval of Ultibro Breezhaler.
UPDATE 2-Europe backs new dual-action Novartis lung drug
LONDON, July 26 - Swiss drugmaker Novartis won an important endorsement of its new inhaled medicine for chronic lung disease on Friday when European regulators recommended approval of Ultibro Breezhaler.
EU regulators back Novartis inhaler, Gilead HIV drug
LONDON, July 26 - European regulators on Friday recommended approval of a new once-daily inhaler for lung disease from Novartis and an HIV medicine from Gilead Sciences.
Novartis vaccine division hit by Bexsero setback
ZURICH - Swiss drugmaker Novartis suffered a fresh blow to the turnaround prospects of its loss-making vaccines division as a key committee advised against including its meningitis B vaccine on Britain's routine vaccination program.
Novartis vaccine division hit by Bexsero setback
* UK committee advises against inclusion in vaccine programme
Novartis lifts full-year outlook after competition delay
ZURICH - Novartis raised its full-year outlook on Wednesday after generic competition to its best-selling blood pressure pill was delayed, granting the Swiss drugmaker a temporary reprieve from patent losses. | Video
UPDATE 2-Novartis lifts full-year outlook after competition delay
* Q2 core EPS down 4 pct at $1.30 vs $1.34 in Reuters poll
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Trading Report for (NVS). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Plunkett Research, Ltd.
|
$99.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

